{
    "name": "binimetinib",
    "comment": "Rx",
    "other_names": [
        "Mektovi"
    ],
    "classes": [
        "Antineoplastics",
        "MEK Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/mektovi-binimetinib-1000139",
    "pregnancy": {
        "common": [
            "Based on animal reproduction studies and its mechanism of action, fetal harm may occur when binimetinib is administered to a pregnant woman",
            "There are no available clinical data on the use of binimetinib during pregnancy",
            "Advise pregnant women of the potential risk to a fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, oral administration of binimetinib during the period of organogenesis was embryotoxic and an abortifacient in rabbits at doses greater than or equal to those resulting in exposures ~5 times the human exposure at the clinical dose of 45 mg PO BID"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Verify pregnancy status of females of reproductive potential prior to initiating treatment  Advise females of reproductive potential to use effective contraception during treatment with binimetinib and for at least 30 days after the final dose",
                    "Nonhormonal contraceptives should be used during treatment and for at least 30 days after the final dose for patients taking encorafenib and binimetinib"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of binimetinib or its active metabolite in human milk, the effects of binimetinib on the breastfed infant, or on milk production",
            "Because of the potential for serous adverse reactions from binimetinib in breastfed infants, advise women not to breastfeed during treatment with binimetinib and for 3 days after the final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Also see Dosage Modifications",
                "In the COLUMBUS trial, venous thromboembolism (VTE) occurred in 6% of patients receiving binimetinib in combination with encorafenib, including 3.1% of patients who developed pulmonary embolism",
                "In patients with BRAF mutation-positive melanoma receiving binimetinib with encorafenib (n=690), 2 patients (0.3%) developed interstitial lung disease (ILD), including pneumonitis; assess new or progressive unexplained pulmonary symptoms or findings for possible ILD",
                "Hepatotoxicity can occur when binimetinib concomitantly used with encorafenib; monitor liver laboratory tests before initiating, monthly during treatment, and as clinically indicated",
                "Rhabdomyolysis can occur when binimetinib is administered in combination with encorafenib; monitor CPK and creatinine levels prior to initiating treatment, periodically during treatment, and as clinically indicated; withhold, reduce dose, or permanently discontinue based on severity of adverse reaction",
                "Hemorrhage can occur when encorafenib is administered in combination with binimetinib; hemorrhagic events include GI, hemorrhoidal, rectal, and intracranial hemorrhage, and hematochezia; withhold, reduce dose, or discontinue drug (see Dosage Modifications)",
                "Based on findings from animal studies and its mechanism of action, fetal harm may occur when administered to a pregnant woman (see Pregnancy)",
                "Risks associated with combination treatment; refer to the encorafenib prescribing information for additional risk information"
            ],
            "specific": [
                {
                    "type": "Ocular toxicities",
                    "description": [
                        "Serous retinopathy",
                        "In the COLUMBUS trial, serous retinopathy occurred in 20% of patients, including retinal detachment (8%) and macular edema (6%)",
                        "Assess for visual symptoms at each visit",
                        "Perform an ophthalmologic examination at regular intervals for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings",
                        "Retinal vein occlusion",
                        "Retinal vein occlusion (RVO) is a known class-related adverse reaction of MEK inhibitors and may occur",
                        "Perform ophthalmologic evaluation for patient-reported acute vision loss or other visual disturbance within 24 hr",
                        "Uveitis",
                        "Uveitis (eg, iritis and iridocyclitis) reported in patients treated with binimetinib  in combination with encorafenib",
                        "Perform an ophthalmologic evaluation at regular intervals and for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings"
                    ]
                },
                {
                    "type": "Cardiomyopathy",
                    "description": [
                        "Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, reported in patients treated with binimetinib in combination with encorafenib",
                        "Assess ejection fraction by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and then every 2-3 months during treatment",
                        "Safety of binimetinib in combination with encorafenib has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN)",
                        "Closely monitor patients with cardiovascular risk factors"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "All grades of severity are listed unless otherwise indicated",
            "percent": "93"
        },
        {
            "name": "Increased creatinine",
            "percent": "58"
        },
        {
            "name": "Increased creatine phosphokinase",
            "percent": "45"
        },
        {
            "name": "Increased gamma glutamyl transferase",
            "percent": "43"
        },
        {
            "name": "GGT",
            "percent": "41"
        },
        {
            "name": "Fatigue",
            "percent": "36"
        },
        {
            "name": "Nausea",
            "percent": "36"
        },
        {
            "name": "Diarrhea",
            "percent": "30"
        },
        {
            "name": "Anemia",
            "percent": "27-29"
        },
        {
            "name": "Vomiting",
            "percent": "28"
        },
        {
            "name": "Increased AST",
            "percent": "22"
        },
        {
            "name": "ALT",
            "percent": "22"
        },
        {
            "name": "Abdominal pain",
            "percent": "21"
        },
        {
            "name": "Constipation",
            "percent": "20"
        },
        {
            "name": "Rash",
            "percent": "20"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "19"
        },
        {
            "name": "Visual impairment",
            "percent": "18"
        },
        {
            "name": "Serous retinopathy",
            "percent": "18"
        },
        {
            "name": "retinal pigment epithelial dystrophy",
            "percent": "15"
        },
        {
            "name": "RPED",
            "percent": "13"
        },
        {
            "name": "Hemorrhage",
            "percent": "13"
        },
        {
            "name": "Hyponatremia",
            "percent": "13"
        },
        {
            "name": "Pyrexia",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "3"
        },
        {
            "name": "Leukopenia",
            "percent": "4"
        },
        {
            "name": "Lymphopenia",
            "percent": "11"
        },
        {
            "name": "Neutropenia",
            "percent": "11"
        },
        {
            "name": "Peripheral edema",
            "percent": "10"
        },
        {
            "name": "Increased GGT",
            "percent": "10"
        },
        {
            "name": "Grades",
            "percent": "10"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Hypertension",
            "percent": "4"
        },
        {
            "name": "Colitis",
            "percent": "6"
        },
        {
            "name": "Panniculitis",
            "percent": "2.6-6"
        },
        {
            "name": "Drug hypersensitivity",
            "percent": "3"
        },
        {
            "name": "Hypertension",
            "percent": "4"
        },
        {
            "name": "Grades",
            "percent": "5"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Increased AST",
            "percent": "4"
        },
        {
            "name": "ALT",
            "percent": "4"
        },
        {
            "name": "Increased creatine phosphokinase",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3.6"
        },
        {
            "name": "Pyrexia",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3.6"
        },
        {
            "name": "Anemia",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3.6"
        },
        {
            "name": "Increased creatinine",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3.1"
        },
        {
            "name": "Hyponatremia",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Neutropenia",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "or",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Dizziness",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Peripheral edema",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Hemorrhage",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "2.1"
        },
        {
            "name": "Serous retinopathy",
            "percent": "3"
        },
        {
            "name": "RPED",
            "percent": "4"
        },
        {
            "name": "Grades",
            "percent": "2"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Lymphopenia",
            "percent": "4"
        },
        {
            "name": "Grades",
            "percent": "2"
        },
        {
            "name": "or",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "4"
        },
        {
            "name": "Grades",
            "percent": "2"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Vomiting",
            "percent": "4"
        },
        {
            "name": "Grades",
            "percent": "1"
        },
        {
            "name": "and",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Grades",
            "percent": null
        },
        {
            "name": "and",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Grades",
            "percent": null
        },
        {
            "name": "and",
            "percent": null
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": null
        }
    ]
}